Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01787474 · ClinicalTrials.gov registry record · Phase 1

Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1 study of Refractory Acute Myeloid Leukemia and Recurrent Adult Acute Myeloid Leukemia, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT01787474: Completed Phase 1 study of Refractory Acute Myeloid Leukemia and Recurrent Adult Acute Myeloid Leukemia, sponsored by M.D. Anderson Cancer Center.

NCT01787474 is a Phase 1 study of Refractory Acute Myeloid Leukemia and Recurrent Adult Acute Myeloid Leukemia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants, below the 47-participant average among 63 other Refractory Acute Myeloid Leukemia trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01787474, a Phase 1 study of Refractory Acute Myeloid Leukemia and Recurrent Adult Acute Myeloid Leukemia, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This phase I/II trial studies the side effects and best dose of donor natural kill cells and to see how well they work in treating patients with acute myeloid leukemia that does not respond to treatment (refractory) or has come back after a period of improvement (relapsed). Giving natural killer cells after high dose chemotherapy may boost the patient's immune system by helping it see the remaining cancer cells as not belonging in the patient's body and causing it to destroy them (called graft-versus-tumor effect).

Conditions Studied

Refractory Acute Myeloid Leukemia Recurrent Adult Acute Myeloid Leukemia

Interventions

  • OTHER Laboratory Biomarker Analysis
  • DRUG Cytarabine
  • BIOLOGICAL Filgrastim
  • DRUG Fludarabine Phosphate
  • BIOLOGICAL Filgrastim-sndz

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2014-05-19
Est. Completion 2021-06-17
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT01787474 record still lists

NCT01787474 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 47-participant average among 63 other Refractory Acute Myeloid Leukemia trials with a reported enrollment target (36% lower).

The record links to 2 conditions, with Refractory Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT01787474 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT01787474 about?

NCT01787474 is a clinical study titled "Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". This phase I/II trial studies the side effects and best dose of donor natural kill cells and to see how well they work in treating patients with acute myeloid leukemia that does not respond to treatment (refractory) or has come back after a period of improvement (relapsed). Giving natural killer cel...

What is the current status of trial NCT01787474?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2014-05-19. Estimated completion is 2021-06-17.

What conditions does trial NCT01787474 study?

This clinical trial studies the following conditions: Refractory Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia.

What interventions are being tested in trial NCT01787474?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cytarabine (DRUG), Filgrastim (BIOLOGICAL), Fludarabine Phosphate (DRUG), Filgrastim-sndz (BIOLOGICAL).

Who is sponsoring clinical trial NCT01787474?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01787474 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01787474's enrollment target sits among peer trials

30 33rd of 63 higher than 26 of 63 other Refractory Acute Myeloid Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Refractory Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT01787474, the US trial registry maintained by the National Library of Medicine. NCT01787474 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.